Effect of doxazosin on the size of LDL particle in the type 2 diabetic patients with hypertension

Journal of Diabetes and its Complications

Volumn 14, Issue 3, 2000, Pages 135-139

  Tamasawa, Naoki ^a   Matsui, Jun ^a   Ogawa, Yoshiji ^a   Gotoh, Takashi ^a   Hinata, Tsuyoshi ^a   Murakami, Hiroshi ^a   Zhi, Guan Jing ^a   Suda, Toshihiro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Doxazosin; Hypertension; Insulin resistance; Small dense LDL; Type 2 DM

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFECT; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PILOT STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CALCIUM CHANNEL BLOCKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOXAZOSIN; FEMALE; HEMOGLOBIN A; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; MALE;

EID: 0033824103     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(00)00071-4     Document Type: Article

References (20)

1. Calo L., Davis P.A., Cantaro S., Bonfante L., Castrignano R., Carraro G., D'Angelo A. Effect of doxazosin in mild to moderate hypertensive patients with insulin-dependent diabetes mellitus. Acta Diabetol. 35:1998;96-100.
2. Dominguez L.J., Weinberger M.H., Cefalu W.T., Jacobs D.B., Barbagallo M., Walsh M.F., Sowers J.R. Doxazosin lowers blood pressure and improves insulin responses to a glucose load with no changes in tyrosine kinase activity or insulin binding. Am J Hypertens. 8:1995;528-532.
3. Erbey J.R., Robbins D., Forrest K.Y.-Z., Orchard T.J. Low-density lipoprotein size and coronary disease in a childhood-onset type 1 diabetes population. Metabolism. 48:1999;531-534.
4. Fatourechi V., Kennedy F.P., Rizza R.A., Hogan M.J. A prectical guideline for management of hypertension in patients with diabetes. Mayo Clin Proc. 71:1996;53-58.
5. Ferrara L.A., Marotta T., Rubba P., De Simone B., Leccia G., Soro S., Mancini M. Effects of alpha-adrenergic and beta-adrenergic receptor blockade on lipid metabolism. Am J Med. 80:1986;104-108.
6. Fox C. Diabetes and hypertension: an era of clarity or confusion? J Hum Hypertens. 13:1999;S9-S17.
7. Giordano M., Matsuda M., Sanders L., Canessa M.L., DeFronzo R.A. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 44:1995;665-671.
8. Harano Y., Suzuki M., Shinozaki K., Hara Y., Ryomoto K., Kanazawa A., Nishioheda Y., Tsushima M. Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach. Hypertens Res. 19(suppl. 1):1996;S81-S85.
9. Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens. 11:1993;319-325.
10. International Standard Serial Number: the Hypertension Optimal Treatment Study (The HOT Study). Blood Pressure. 2:1993;62-68.
11. Jasik M., Kasperska-Dworak A., Czyzyk A. Effect of nifedipine, captopril and prazosin on secretory function of pancreatic beta-cells in hypertensive patients with type-2 (non-insulin-dependent) diabetes and in hypertensive non-diabetics. Diabetes Res Clin Pract. 33:1996;59-66.
12. Lithell H.O. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am J Hypertens. 9:1996;150S-154S.
13. Marotta T., Ferrara L.A., Di Marino L., Mancini M., Annuzzi G., Russo O., D'Orta G., Lucarelli C., Rossi F. Factors affecting lipoprotein lipase in hypertensive patients. Metabolism. 44:1995;712-718.
14. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419.
15. Mishima Y., Ando M., Kuyama A., Ishioka T., Kibata M. A simple method for identifying particle size of low-density lipoprotein using PAG electrophoresis: comparison between LipoPhor and LipoPrint LDL system. J Jpn Atheroscler Soc. 25:1997;67-71.
16. Pyorala K., Pedersen T.R., Kjekshus J., Faergeman O., Olssen A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 20:1997;614-620.
17. Shieh S.M., Shen W.H., Shen D.C., Fun M.M., Chen Y.D., Reaven G.M. Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens. 5:1992;827-831.
18. Sowers J.R., Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension. 26:1995;869-879.
19. Turner R.C. The UK prospective diabetes study. A review. Diabetes Care. 21:1998;C35-C38.
20. Veelken R., Schmieder R.E. Overview of alpha 1-adrenoceptor antagonism and recent advances in hypertensive therapy. Am J Hypertens. 9:1996;139S-149S.